RIGL on Nasdaq
RIGEL PHARMACEUTICALS INC
American pharmaceutical preparations company based in San Francisco.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Ironwood Pharmaceuticals, Xeris Biopharma Holdings, Inc. or Evolus, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
42.6%Operating margin3
124.7%Net margin3
64.1%Revenue growth, 20253
93.8%Return on equity3
0.13×Debt to equity3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Gross Product brought in 83% of the revenue RIGEL PHARMACEUTICALS INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Gross Product | $147.1M | $209.9M | $310.0M |
| Release Of Share Cost Liability | $0 | $0 | $40.0M |
| Royalty Delivery Of Drug Supplies And Others | $11.4M | $20.4M | $19.1M |
| Development Milestones | $75.0K | $0 | $3.0M |
| Government Contract | $1.1M | $0 | $265.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue3¢$19.6M
- Research and development4¢$33.3M
- Selling, general and admin15¢$115.9M
- Income tax31¢$245.2M
- Profit47¢$367.0M
Out of $294.3M in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$75.7M
Out of $75.7M of cash from operations.3
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $294.3M | $179.3M | $116.9M |
| Cost of product sales | $19.6M | $18.6M | $7.1M |
| Research and development | $33.3M | $23.4M | $24.5M |
| Selling, general and administrative | $115.9M | $113.1M | $105.7M |
| Total costs and expenses | $168.8M | $155.1M | $137.4M |
| Income (loss) from operations | $125.5M | $24.2M | -$20.5M |
| Interest income | $3.7M | $2.1M | $2.3M |
| Interest expense | -$7.3M | -$7.9M | -$6.9M |
| Income (loss) before income taxes | $121.8M | $18.4M | -$25.1M |
| (Benefit from) provision for income taxes | -$245.2M | $881.0K | $0 |
| Net income (loss) | $367.0M | $17.5M | -$25.1M |
| Basic (in dollars per share) | $20.40 | $0.99 | -$1.44 |
| Diluted (in dollars per share) | $19.48 | $0.99 | -$1.44 |
| Basic (in shares) | 18.0M shares | 17.6M shares | 17.4M shares |
| Diluted (in shares) | 18.8M shares | 17.7M shares | 17.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $40.6M | $56.7M | ||
| Short-term investments | $114.4M | $20.6M | ||
| Accounts receivable, net | $51.8M | $41.6M | ||
| Inventories | $11.5M | $6.0M | ||
| Prepaid and other current assets | $21.9M | $10.2M | ||
| Total current assets | $240.2M | $135.1M | ||
| Intangible assets, net | $24.7M | $27.1M | ||
| Deferred income tax asset | $245.9M | $0 | ||
| Operating lease right-of-use assets | $920.0K | $246.0K | ||
| Other assets | $1.9M | $1.5M | ||
| Total assets | $513.6M | $164.0M | ||
| Accounts payable | $7.2M | $3.3M | ||
| Accrued compensation | $11.9M | $10.1M | ||
| Accrued research and development | $5.5M | $4.1M | ||
| Acquisition related liabilities | $5.0M | $0 | ||
| Revenue reserves and refund liability | $27.7M | $26.4M | ||
| Loans payable, net, current portion | $29.8M | $7.3M | ||
| Other current liabilities | $11.5M | $11.8M | ||
| Lease liabilities, current portion | $614.0K | $285.0K | ||
| Total current liabilities | $99.2M | $63.3M | ||
| Acquisition-related liabilities | $0 | $5.0M | ||
| Long-term portion of lease liabilities | $395.0K | $0 | ||
| Long-term portion of loans payable, net | $22.5M | $52.4M | ||
| Other long-term liabilities | $0 | $40.0M | ||
| Total liabilities | $122.1M | $160.7M | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 400,000,000 shares authorized; 18,310,934 and 17,710,216 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $18.0K | $18.0K | ||
| Additional paid-in capital | $1.4B | $1.4B | ||
| Accumulated other comprehensive income | $181.0K | $10.0K | ||
| Accumulated deficit | -$1.0B | -$1.4B | ||
| Total stockholders equity | $391.5M | $3.3M | -$28.6M | -$13.6M |
| Total liabilities and stockholders equity | $513.6M | $164.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued (in shares) | 18.3M shares | 17.7M shares | ||
| Common stock, shares outstanding (in shares) | 18.3M shares | 17.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $40.6M | $56.7M | ||
| Short-term investments | $114.4M | $20.6M | ||
| Accounts receivable, net | $51.8M | $41.6M | ||
| Inventories | $11.5M | $6.0M | ||
| Prepaid and other current assets | $21.9M | $10.2M | ||
| Total current assets | $240.2M | $135.1M | ||
| Intangible assets, net | $24.7M | $27.1M | ||
| Deferred income tax asset | $245.9M | $0 | ||
| Operating lease right-of-use assets | $920.0K | $246.0K | ||
| Other assets | $1.9M | $1.5M | ||
| Total assets | $513.6M | $164.0M | ||
| Accounts payable | $7.2M | $3.3M | ||
| Accrued compensation | $11.9M | $10.1M | ||
| Accrued research and development | $5.5M | $4.1M | ||
| Acquisition related liabilities | $5.0M | $0 | ||
| Revenue reserves and refund liability | $27.7M | $26.4M | ||
| Loans payable, net, current portion | $29.8M | $7.3M | ||
| Other current liabilities | $11.5M | $11.8M | ||
| Lease liabilities, current portion | $614.0K | $285.0K | ||
| Total current liabilities | $99.2M | $63.3M | ||
| Acquisition-related liabilities | $0 | $5.0M | ||
| Long-term portion of lease liabilities | $395.0K | $0 | ||
| Long-term portion of loans payable, net | $22.5M | $52.4M | ||
| Other long-term liabilities | $0 | $40.0M | ||
| Total liabilities | $122.1M | $160.7M | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 400,000,000 shares authorized; 18,310,934 and 17,710,216 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $18.0K | $18.0K | ||
| Additional paid-in capital | $1.4B | $1.4B | ||
| Accumulated other comprehensive income | $181.0K | $10.0K | ||
| Accumulated deficit | -$1.0B | -$1.4B | ||
| Total stockholders equity | $391.5M | $3.3M | -$28.6M | -$13.6M |
| Total liabilities and stockholders equity | $513.6M | $164.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued (in shares) | 18.3M shares | 17.7M shares | ||
| Common stock, shares outstanding (in shares) | 18.3M shares | 17.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $367.0M | $17.5M | -$25.1M |
| Stock-based compensation expense | $12.7M | $12.4M | $8.8M |
| (Gain) loss on sale and disposal of fixed assets | $0 | -$79.0K | $266.0K |
| Depreciation and amortization | $2.4M | $2.2M | $1.2M |
| Deferred income tax benefit | -$245.9M | $0 | $0 |
| Release of cost share liability | -$40.0M | $0 | $0 |
| Net amortization of discount on short-term investments and term loans | -$1.1M | -$709.0K | -$479.0K |
| Accounts receivable, net | -$10.1M | -$11.1M | $9.8M |
| Inventories | -$5.6M | $764.0K | $1.2M |
| Prepaid and other current and non-current assets | -$11.8M | -$3.4M | $2.1M |
| Right-of-use assets | -$674.0K | $615.0K | $1.1M |
| Accounts payable | $3.9M | -$3.8M | -$366.0K |
| Accrued compensation | $1.8M | $1.5M | -$190.0K |
| Accrued research and development | $1.5M | $560.0K | -$4.2M |
| Revenue reserves and refund liability | $1.3M | $10.8M | $3.5M |
| Other current and long-term liabilities | -$285.0K | $5.0M | -$2.2M |
| Lease liability | $724.0K | -$692.0K | -$1.1M |
| Net cash provided by (used in) operating activities | $75.7M | $31.5M | -$5.7M |
| Maturities of short-term investments | $61.1M | $39.7M | $41.6M |
| Purchases of short-term investments | -$153.5M | -$35.3M | -$31.2M |
| Capital expenditures | $0 | -$36.0K | $0 |
| Payments for acquisition of intangible assets | $0 | -$360.0K | -$15.0M |
| Proceeds from sale of property and equipment | $0 | $98.0K | $259.0K |
| Net cash (used in) provided by investing activities | -$92.4M | $4.1M | -$4.3M |
| Net proceeds from term loan financing | $0 | $0 | $19.9M |
| Principal payments of term loans | -$7.5M | $0 | $0 |
| Net proceeds from issuance of common stock from equity plans | $8.1M | $2.0M | $1.0M |
| Closing purchase price payment related to asset acquisition | $0 | -$10.0M | $0 |
| Cost share payments to a collaboration partner | $0 | -$3.6M | -$2.6M |
| Net cash provided by (used in) financing activities | $601.0K | -$11.6M | $18.4M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$16.1M | $24.0M | $8.3M |
| Interest paid | $6.6M | $7.0M | $5.8M |
| Income taxes paid | $1.1M | $331.0K | $81.0K |
| Increase in right-of-use assets and lease liability | $1.2M | $0 | $0 |
| Acquisition-related liabilities | $5.0M | $5.0M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led RIGEL PHARMACEUTICALS INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerRaul R. Rodriguez Jan 28, 2015 to now12
- Chief executive officerJames M. Gower Jan 27, 2006 to Mar 3, 201413
- ChairJames M. Gower Jan 27, 2006 to Mar 3, 201413
- PresidentRaul R. Rodriguez Jun 1, 2010 to now14
- Chief financial officerDean L. Schorno Jun 6, 2018 to now15
- Chief financial officerJames H. Welch Jan 27, 2006 to Jan 27, 200616
- Chief financial officerRyan D. Maynard Jun 2, 2006 to Nov 7, 201717
- Chief operating officerRaul R. Rodriguez Jan 27, 2006 to Mar 3, 201418
Board members and other officers (31)
- EVP, Chief Medical OfficerAlison L. Hannah Jul 10, 2026 to now19
- EVP, Chief Medical OfficerLisa Rojkjaer Mar 29, 2024 to now20
- EVP, GC & Corp SecRaymond J. Furey Dec 16, 2022 to now21
- EVP, Chief Commercial OfficerDavid A. Santos Aug 20, 2020 to now22
- Chief Medical OfficerWolfgang Dummer Nov 14, 2019 to Feb 6, 202323
- EVP Human ResourcesStacy Markel Mar 23, 2018 to Mar 22, 201924
- Principal Accounting OfficerNelson Cabatuan Dec 22, 2017 to May 15, 202025
- Chief Medical OfficerAnne-Marie Duliege Mar 14, 2016 to Mar 22, 201926
- EVP &Chief Commercial OfficerEldon C. Mayer Iii. Oct 11, 2016 to Nov 20, 201927
- Sr. VP ResearchEsteban Masuda Oct 11, 2016 to Nov 20, 201928
- VP Bus. Dev.& Alliance Mgmt.Joseph Lasaga Oct 11, 2016 to Nov 20, 201929
- VP Intel. Prop.& Gen.CounselDolly Vance Jan 27, 2006 to Sep 16, 202230
- Ex. VP Chief Sci. OfficerDonald G. Payan Jan 27, 2006 to Sep 1, 201631
- Sr. VP Medical DevelopmentElliot B. Grossbard Jan 27, 2006 to Jan 28, 201632
- Sr. V.P. Pharmaceutical Scs.Robin D. G. Cooper Jan 27, 2006 to Feb 4, 200833
- Board memberMark W. Frohlich Mar 10, 2025 to now34
- Board memberAlison L. Hannah May 18, 2021 to now35
- Board memberKamil Ali-Jackson Dec 17, 2021 to now36
- Board memberJane Wasman Apr 3, 2019 to now37
- Board memberBrian L. Kotzin Aug 23, 2017 to May 29, 202438
- Board memberGregg Anthony Lapointe Nov 2, 2017 to now39
- Board memberRaul R. Rodriguez Jan 28, 2015 to now12
- Board memberKeith Katkin Jul 1, 2015 to May 21, 202140
- Board memberBradford S. Goodwin Jan 25, 2007 to May 21, 202141
- Board memberDonald G. Payan Jan 27, 2006 to Sep 1, 201631
- Board memberAlan D. Frazier Feb 14, 2006 to Aug 8, 200642
- Board memberGary A. Lyons May 31, 2006 to Jul 12, 202343
- Board memberHollings Renton May 31, 2006 to May 28, 201344
- Board memberPeter S. Ringrose May 31, 2006 to May 18, 201845
- Board memberWalter H. Moos May 31, 2006 to now46
- Board memberStephen A. Sherwin Jun 1, 2006 to May 12, 201647
Timeline
Filings
293 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 58 major events, 136 insider forms, 38 large holders, 41 other. The latest 20:
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 4, 2026S-8 EDGAR
- Aug 4, 20268-K EDGAR
- Aug 4, 202610-Q EDGAR
- Jul 10, 20264 EDGAR
- Jul 1, 20268-K EDGAR
- Jun 24, 20264 EDGAR
- Jun 22, 2026144 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 17, 20268-K EDGAR
- Jun 3, 20264 EDGAR
The 293 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 38 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 13, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- May 7, 2026SCHEDULE 13G
- Mar 27, 2026SCHEDULE 13G/A
- Feb 9, 2026SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Oct 7, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- Aug 5, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARRaul R. Rodriguez, President
- 15
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGARRaymond J. Furey, EVP, GC & Corp Sec
- 22
- 23
- 24SEC EDGARStacy Markel, EVP Human Resources
- 25
- 26
- 27
- 28SEC EDGAREsteban Masuda, Sr. VP Research
- 29
- 30
- 31
- 32
- 33
- 34SEC EDGARMark W. Frohlich, Board member
- 35SEC EDGARAlison L. Hannah, Board member
- 36SEC EDGARKamil Ali-Jackson, Board member
- 37SEC EDGARJane Wasman, Board member
- 38SEC EDGARBrian L. Kotzin, Board member
- 39SEC EDGARGregg Anthony Lapointe, Board member
- 40SEC EDGARKeith Katkin, Board member
- 41SEC EDGARBradford S. Goodwin, Board member
- 42SEC EDGARAlan D. Frazier, Board member
- 43SEC EDGARGary A. Lyons, Board member
- 44SEC EDGARHollings Renton, Board member
- 45SEC EDGARPeter S. Ringrose, Board member
- 46SEC EDGARWalter H. Moos, Board member
- 47SEC EDGARStephen A. Sherwin, Board member